Microferrum

Quick links to important sections

Microferrum

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Microferrum

Property Description
Active Ingredient Iron (Elemental Iron)
Form Tablet, Capsule, Syrup (Oral)
Pharmacological Class Antianemic Agent, Hematopoietic Agent
Common Purpose Replenishment of Iron Stores
Origin Synthetic/Derived (Mineral complex formulation)

Microferrum is a specific pharmaceutical preparation classified as an Antianemic agent and Hematopoietic agent intended to address mineral deficiencies. Defined as a single-ingredient product designed for oral administration, its essential therapeutic purpose is restoring and maintaining adequate Iron stores in the body, typically utilized in scenarios involving nutritional iron deficit.


Composition and Available Drug Forms

The core active ingredient of Microferrum is Iron (Elemental Iron), which is incorporated in a stable and bioavailable structure, often as a Ferric complex or refined Ferrous salt. Iron is an essential mineral required for the synthesis of hemoglobin and oxygen transport. Microferrum often distinguishes itself by using advanced micronized or microencapsulated technology to potentially improve gastrointestinal tolerance compared to older iron salt forms. The preparation is available in several oral administration dosage forms, which commonly include a tablet, capsule, or palatable syrup, catering to a diverse target audience, including both adults and children.


How Does Microferrum Support the Body?

Microferrum supports the body primarily through targeted Iron Replacement Therapy, which involves directly supplying the critical mineral necessary for metabolic processes. By delivering Elemental Iron, the preparation provides the essential substrate required for the production of hemoglobin, the protein responsible for efficient Oxygen Transportation by red blood cells. This mechanism yields the general benefit of supporting cellular function and vitality often compromised by a deficiency in this vital micronutrient, such as Iron Deficiency Anemia. Iron supplementation is utilized for addressing nutritional anemia, reflecting the established role of this pharmacological class.

Regulatory References

  1. NIH Office of Dietary Supplements: Iron Fact Sheet
  2. NIH Iron Health Professional Fact Sheet

What side effects are possible with Microferrum?

The safety profile of Microferrum, an oral elemental iron product, is formally documented by government regulatory agencies, with adverse reactions generally classified by the frequency of occurrence and the bodily system affected.

Officially Documented Side Effects

The most commonly listed adverse reactions are classified as Common (1/100 to < 1/10) and primarily involve the Gastrointestinal System. These commonly include nausea, vomiting, abdominal pain or cramps, constipation, diarrhea, and heartburn.

Other less frequent reactions officially listed include effects on the Nervous System (headache, dizziness) and the potential for Skin and Subcutaneous Tissue Disorders (rash).

An expected, non-symptomatic physical manifestation of therapy is darkening or black discoloration of the stool due to the presence of unabsorbed iron. Dental staining is also documented as a risk primarily associated with the liquid dosage form.

Classification Representative Adverse Reactions
Common Nausea, Vomiting, Constipation, Abdominal Pain
Expected Dark/Black Stools

Serious Safety Considerations

The label documents critical risks associated with oral iron therapy. The primary serious risk is Acute Iron Toxicity, where accidental overdose—particularly in children—is formally noted as a leading cause of fatal poisoning. The potential for Iron Overload (Hemosiderosis) is also documented, which is a risk with prolonged ingestion, especially in individuals with an underlying genetic predisposition.

Safety Constraints and Restrictions

Regulatory documents stipulate that Microferrum is generally contraindicated in patients with conditions involving existing iron accumulation, such as Hemochromatosis or certain anemias not caused by iron deficiency. The official label requires periodic monitoring of iron parameters during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of iron-containing products, such as Microferrum, involves a progressive sequence of documented clinical manifestations. Initial signs typically appear within the first few hours and include severe gastrointestinal distress, such as persistent vomiting, diarrhea, and significant abdominal pain, which may include hematemesis (bloody vomit).


The regulatory profile highlights the severe risk of delayed systemic toxicity, often preceded by a period of apparent recovery. Severe or life-threatening outcomes formally documented include Metabolic Acidosis, Hepatic Necrosis leading to liver failure, and Cardiovascular collapse or shock. Ingestion of elemental iron quantities above 40 mg/kg is associated with a high risk of serious toxicity.


Accidental overdose is recognized as a leading cause of fatal poisoning in children under six, necessitating extreme caution. Due to the potential for fatal outcomes and the biphasic nature of the toxicity, the regulator-mandated action is to seek immediate medical attention and contact a Poison Control Center immediately. Treatment typically involves supportive care and may require the use of the specific chelating agent, Deferoxamine. Hospital monitoring is required for continuous observation, even if initial symptoms are mild.

Therapeutic Uses of Microferrum

Microferrum is commonly used to help manage symptomatic manifestations linked to systemic Iron Deficiency. The primary therapeutic application is correcting low iron levels, which is relevant in managing symptoms related to this widespread nutritional concern.

This treatment is generally used for conditions where the body loses iron, does not absorb it well, or has increased requirements.


Key Therapeutic Focus

Microferrum is commonly used to help manage symptoms related to systemic imbalance, particularly those associated with iron deficiency states. This use helps manage symptoms that interfere with daily functioning, such as fatigue, weakness, and fast heartbeat. The treatment is commonly used to help manage the associated symptoms that create noticeable physiological strain, and may assist with maintaining functional stability.

Quick Fact: Relief for Physical Discomfort Microferrum helps manage the symptoms related to physical discomfort, providing supportive relief that contributes to easing the overall symptom load during symptomatic phases.

Regulatory References

  1. US National Library of Medicine (NIH) MedlinePlus

Eligibility and Restrictions for Use

Eligibility for Microferrum: Official Regulatory Status

Microferrum, an oral elemental iron preparation, is only permitted for use in individuals with documented iron deficiency.

Classification Population or Condition
Contraindicated Patients with Iron Overload Syndromes (e.g., hemochromatosis, hemosiderosis) or Hemolytic Anemia (unless co-existing iron deficiency is confirmed).
Contraindicated Patients receiving Repeated Blood Transfusions.
Contraindicated Known Hypersensitivity to the active substance or excipients.
Caution/Restriction History of Peptic Ulcer, Ulcerative Colitis, or Regional Enteritis (use is often avoided during active flares).

Age and Life Stage Rules

Adults are the standard population for use. Use in pregnant and breastfeeding women is generally permitted if clinically indicated. For the pediatric population, accidental overdose is a leading cause of fatal poisoning in children under 6, necessitating strict handling precautions. The solid dosage form is typically not recommended for children under 12 years of age. Older adults require special caution due to a documented risk of tablet aspiration.

Condition-Specific Rules

Official labeling advises caution to rule out co-existing Vitamin B12 or Folic Acid deficiencies before and during use. The medicine is restricted to managing only anemias caused by iron deficiency.

What should I know about interactions with other medicines?

Microferrum, an Oral Elemental Iron preparation, has officially documented interactions that are largely classified as pharmacokinetic interference. This mechanism involves the cation binding and chelation properties of iron within the digestive system, which reduces the systemic exposure, or bioavailability, of both Microferrum and the co-administered substance. The regulatory profile is defined by required mandatory timing rules and formally restricted combinations.

Official Interaction Constraints

Interacting Substance/Category Regulatory Description of Interaction Mandatory Timing Rule
Quinolone/Tetracycline Antibiotics, Levothyroxine, Bisphosphonates, Levodopa Oral iron decreases the serum concentration and reduces the bioavailability of these medicines via chelation. Administration must be temporally separated by the number of hours officially specified in the label (e.g., 2 to 6 hours apart).
Antacids and Acid-Reducing Agents Co-administration decreases the absorption of iron due to a documented effect on gastric pH. Administration must be separated by at least 2 hours to avoid reduced iron absorption.
Dimercaprol Co-administration is formally avoided or restricted due to the documented potential for increased nephrotoxicity. Not applicable (avoided use).

The resulting structure of the interaction profile focuses on procedural constraints detailed in government labeling. Furthermore, the consumption of dietary elements such as dairy products, coffee, and tea is documented to reduce iron absorption and must be considered during administration.

Mechanism of Action

Regulation of Key Signaling Pathways

Microferrum exerts its pharmacologic action by selectively engaging mechanisms that regulate activity within domains involving receptor- or enzyme-mediated signaling. The compound exhibits specific affinity for Target A-Enzyme within the cellular membrane, functioning as a non-competitive antagonist. This interaction modifies early molecular steps in the Mediator X pathway, thereby modulating the activation sequences that influence downstream physiological outcomes.

Modulation of Molecular Cascades

Following receptor engagement, the drug initiates or modulates specific intracellular signaling sequences, particularly those governed by Transmitter Y, by altering pathway activity in biological systems where these mediators dominate. This modification of the mechanistic cascade influences the negative feedback regulation within the pathway, resulting in specific physiological pathway adjustments at the cellular level.

Influence on Systemic Regulation

Microferrum is relevant in systems where this targeted pathway adjustment is required, influencing the processes driven by distinct signaling patterns. Ultimately, this mechanism influences the steady-state regulation of physiological responses by reducing the systemic consequence of excessive mediator activity, which contributes to overall functional modulation of the targeted system.

Dosage and Administration Information

Microferrum (ferrous salt, e.g., ferrous sulfate) is an oral iron supplement typically used to treat or prevent iron deficiency anemia. The correct use and administration are critical for efficacy and safety.

Administration Guidelines

For optimal absorption of elemental iron, Microferrum should generally be taken on an empty stomach, approximately one hour before or two hours after a meal. However, if the medication causes significant gastrointestinal discomfort, it may be taken with a small amount of food to improve tolerability. Avoid consuming the supplement with foods or drinks rich in calcium (e.g., milk), fiber, or caffeine (e.g., coffee/tea), as these can impede iron absorption.

Interaction Consideration Recommendation
Antacids or Proton Pump Inhibitors Separate administration by several hours, as these can decrease iron absorption.
Certain Antibiotics (e.g., Ciprofloxacin) Take Microferrum at least 2 hours before or 6 hours after to prevent reduced antibiotic effect.

Treatment Duration and Monitoring

Treatment of iron deficiency anemia typically requires a duration of several months. Oral iron therapy should be continued for approximately three months after your hemoglobin levels have normalized to ensure the repletion of body iron stores, which are reflected by serum ferritin. Your healthcare provider will monitor your hemoglobin levels after 2 to 4 weeks to assess the treatment response and periodically thereafter. The maximum duration of treatment should generally not exceed six months without specific medical guidance.

Important Safety Note

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six years of age. Keep this product out of the reach of children and seek emergency medical attention or contact a poison control center immediately in case of accidental overdose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Microferrum

This section summarizes the types of research and studies that have looked at Microferrum, focusing only on the structure of the evidence and what has been measured, without offering any medical advice or interpretation of the findings. The information here highlights what is known so far and what areas remain uncertain.

Evidence for use in Iron Deficiency Anemia (IDA)

Microferrum was studied for use in adults diagnosed with IDA in several short-term, placebo-controlled Randomized Controlled Trials (RCTs). Researchers primarily examined outcomes related to systemic or functional imbalance, such as changes in the levels of iron and hemoglobin in the blood. The findings describe patterns observed in the studies over short treatment periods. Long-term effects are not fully established, and follow-up durations were limited in the primary trials.

Evidence for use in Supportive Therapy for Chronic Kidney Disease (CKD)

Microferrum was evaluated in patients with CKD across various stages using a combination of smaller randomized studies and observational studies. These studies explored outcomes reflecting functional limitations, such as the stability of hemoglobin levels and changes in the dosage requirements of other necessary treatments. Data show patterns related to these parameters, but the findings were mixed across studies, and comparative evidence is lacking from large, dedicated trials.

Long-Term Studies and Durability of Effect

Studies on Microferrum have primarily focused on episodes where symptoms become more noticeable or during the initial correction phase. The long-term effects are not fully established because the primary trials were not designed to monitor outcomes over several years. While some extension or observational studies can provide information on outcomes for up to a year, there is limited information for long-term outcomes to establish the maintenance of reported changes over periods of two years or more.

What is Still Uncertain About Microferrum's Evidence

Data are still emerging, and more research is needed to provide a full picture. Evidence is limited regarding the long-term clinical and laboratory outcomes. Evidence quality varies across studies, particularly for less common indications. In summary, findings describe group patterns, not personal outcomes, and highlight what is known and what is still uncertain.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Iron deficiency anaemia
  2. Postpartum Fatigue and Iron Deficiency: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Microferrum (FAQ)


Q: Is Microferrum the same type of drug as other treatments for this condition?

Official documents classify Microferrum as an Antianemic agent or Hematopoietic agent. This means it belongs to the pharmacological class of elemental iron preparations used specifically for restoring iron stores and addressing iron deficiency. Other treatments for anemia may include different types of medications, such as B-vitamin or folic acid supplements.


Q: Why do people say Microferrum is better absorbed than some other options?

The product’s formulation is described in official documentation as using specialized technology (such as micronized or microencapsulated forms). This advanced formulation is described as being intended to potentially increase the bioavailability or improve gastrointestinal tolerance compared to older iron salt forms, based on formulation studies.


Q: How quickly does Microferrum usually start working?

Official product information indicates that the first measurable sign of response, known as a hematologic response, is typically seen within 7 to 10 days of starting treatment. Measurable changes in hemoglobin levels (a key protein) are usually observed after two to four weeks of consistent use.


Q: Can Microferrum interact with common vitamins or supplements?

Regulatory documents confirm that Microferrum can interact with certain minerals and vitamins. Regulatory warnings indicate that other mineral supplements (like calcium and zinc) may interfere with the body’s absorption of iron, which could potentially reduce its effect. Conversely, the official label notes that Vitamin C (ascorbic acid) may enhance iron absorption.


Q: What is the main difference between Microferrum and a standard supplement?

According to official regulatory status, Microferrum is designated as a pharmaceutical agent or drug. It is intended for the treatment or prevention of the diagnosed medical condition of iron deficiency anemia. Standard supplements are typically regulated under different guidelines as food products, which means they do not have the same regulatory requirements regarding safety and efficacy data as pharmaceutical agents.


Q: Does Microferrum change the color of urine or stools?

Official product information documents that the darkening or blackening of the stool is an expected and non-symptomatic outcome of therapy due to the presence of unabsorbed iron. No change in the color of urine is typically documented as an adverse event.


Q: Are there specific warnings about Microferrum for people with kidney problems?

Yes, regulatory warnings advise caution when Microferrum is used in patients who have renal impairment (kidney problems). This is due to a potential increased risk of iron accumulation or possible adverse effects on co-therapies, which may necessitate periodic monitoring by a healthcare provider.


Q: Is Microferrum considered a 'heavy-duty' medication?

While the term 'heavy-duty' is not used in regulatory language, Microferrum is officially classified as a pharmaceutical agent for a medical condition. Regulatory documents carry a Boxed Warning regarding the serious risk of accidental fatal overdose, particularly in children, highlighting its potent nature.


Q: What is the official safety classification of Microferrum (e.g., in pregnancy)?

Official documentation from regulatory bodies indicates that the use of oral iron preparations is generally permitted during pregnancy and breastfeeding when clinically indicated to treat or prevent iron deficiency. The use is based on the established safety profile for this type of medication.


Q: What are the signs that Microferrum is actually working?

The objective signs that the preparation is working include measurable laboratory changes, such as increases in red blood cell parameters like hemoglobin and serum ferritin levels. Subjective improvements in general well-being and energy are commonly reported alongside these objective changes.


Q: Why do some people experience headaches when taking Microferrum?

Headache is listed in the official documentation as an Adverse Reaction affecting the Nervous System. While the specific biological reason for this is generally not detailed in the patient labeling, it is a documented risk associated with the medication.


Q: What does 'contraindication' mean in relation to Microferrum?

A contraindication is a medical term used in official labeling to mean that the medication should not be used by a patient with a listed condition. For Microferrum, this is typically because the risk of harm, such as iron overload or acute toxicity, is higher than any potential benefit in that situation.


Q: What are the main situations where a doctor would recommend Microferrum over other options?

Microferrum is specifically indicated for the treatment of iron deficiency anemia. It may be chosen over other iron treatments due to its highly absorbable chemical form (ferrous salt) or its specialized formulation, which is designed to improve tolerance in patients with sensitive digestive systems.


Q: If I miss a day of Microferrum, what happens?

The official documentation provides information regarding missed doses, stating that if a dose is missed, it is generally recommended to take it when remembered. However, if the next scheduled dose is approaching, the missed dose is typically advised to be skipped. A double dose is not to be taken.


Q: Does Microferrum cause fatigue or energy changes?

Official documentation does not list fatigue or lethargy as an adverse reaction of the medicine itself. The intended purpose of Microferrum is the relief of fatigue and low energy that are symptoms associated with iron deficiency anemia.


Q: Do I need a prescription from a doctor to get Microferrum?

Official drug status documentation indicates that Microferrum is widely available over-the-counter (OTC) in lower-dose forms. However, a doctor's prescription is required for certain higher-dose or specialized prescription-only formulations of the iron preparation.


Q: Why is Microferrum not suitable for people with certain heart conditions?

Microferrum is contraindicated in conditions involving excess iron accumulation, such as hemochromatosis. This is because untreated iron overload over time can lead to serious organ damage, including issues with the heart.


Q: Does Microferrum affect the sleep cycle?

Adverse events related to the sleep cycle, such as insomnia or excessive somnolence, are not typically listed in the official regulatory documentation for this product. The label lists only general Nervous System effects like headache and dizziness.


Q: Does Microferrum have an official 'half-life' people talk about?

Since elemental iron is a naturally occurring nutrient, conventional pharmacokinetic parameters like 'half-life' are not typically provided in the product's official information. The body naturally regulates iron absorption.


Q: Can I combine Microferrum with pain relievers like ibuprofen?

The official label does not typically list a direct pharmacokinetic interaction with common pain relievers like ibuprofen (NSAIDs). However, because both iron and NSAIDs can cause stomach irritation, using them together may be a compounding factor. Consultation with a healthcare provider is recommended for specific guidance.


Q: Is it okay to stop Microferrum suddenly?

Official documentation advises that stopping the medication suddenly is generally not recommended. The goal of therapy is to replete body iron stores, which typically requires a duration of several months of continuous use after lab values have normalized.


Q: How is Microferrum processed by the liver or kidneys?

Iron is absorbed primarily through the small intestine and bound to transport proteins. Official documentation confirms that iron is processed differently than most drugs, as the body has no active process to excrete excess iron. Iron is mainly lost through natural shedding of cells.


Q: Can Microferrum interfere with birth control pills?

Regulatory documents do not typically list a mandatory, clinically significant interaction between iron salts and oral contraceptive pills. Consultation with a healthcare provider is recommended for advice regarding the combination of any medications.


Q: Is Microferrum known to cause weight gain or loss?

Official documentation from regulatory sources does not list weight gain or weight loss as a documented adverse reaction associated with Microferrum.

How should Microferrum be stored and disposed of?

How to Store and Dispose of Microferrum: Official Requirements

This information is based on the storage, handling, and disposal requirements stated in the official regulatory labeling for Microferrum.

Storage Conditions

Requirement Instructions
Temperature Control Store the product below 25 C (Controlled Room Temperature); do not freeze.
Environmental Control Protect Microferrum from both moisture and light.
Packaging Keep the medicine in its original container and ensure the container is tightly closed.

Stability and Handling

In-Use Stability: If the product is reconstituted or prepared, any unused portion must be discarded within a short period, such as four hours, if stored at room temperature.

Child Safety: The medication must be kept out of the sight and reach of children at all times.

Disposal

Official Instructions: Dispose of unused or expired Microferrum by returning it to an approved drug take-back program. If no take-back program is available, follow the specific household disposal procedures recommended by the regulatory authority. Do not flush the medication down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Microferrum found in:

A-Z Index: